Clinical data | |
---|---|
Trade names | Vosevi (combination with sofosbuvir and velpatasvir) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
PDB ligand | |
Chemical and physical data | |
Formula | C40H52F4N6O9S |
Molar mass | 868.94 g·mol−1 |
3D model ( JSmol) | |
Density | 1.4±0.1 [1] g/cm3 |
| |
|
Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/ 4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir. [2] The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017. [3]
On 18 July 2017, Vosevi was approved by the US Food and Drug Administration. [4]